Search clinical trials for: JNJ-39393406

Total 867 results

Janssen Research & Development, LLC

Recruiting

A Study of JNJ-87890387 for Advanced Solid Tumors

Advanced Solid Tumors

United States, France, Spain
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

Neoplasms | Myeloproliferative Disorders | Essential Thrombocythemia | Myelofibrosis

United States, Spain, France, Canada
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Lymphoma, Non-Hodgkin | Leukemia, Lymphocytic, Chronic, B-Cell

United States, Korea, Republic of, United Kingdom, Taiwan, Israel, Spain, Australia, France
Janssen Pharmaceutical K.K.

Completed

A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant

Japan
Janssen Research & Development, LLC

Completed

A Study to Investigate the Whole Body Distribution and Radiation Dosimetry of the Positron Emission Tomography Ligand Fluoride-18 (18F)-JNJ-64326067 in Healthy Participants

Healthy

United States
Johnson & Johnson Pharmaceutical Research & Development...
Janssen Pharmaceutica N.V., Belgium

Completed

A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.

Pharmacokinetics | Advanced Malignancies | Solid Malignancies | Protein Kinase Inhibitors | Maximum Tolerated Dose | Antineoplastic Protocols | Clinical Trial, Phase 1
Janssen Research & Development, LLC

Recruiting

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Multiple Myeloma

United States, Belgium, China, Israel, Netherlands, Spain, Japan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy

Prostate Adenocarcinoma | Stage IIB Prostate Cancer AJCC v8

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Janssen Research & Development, LLC

Completed

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression (SUSTAIN-3)

Depressive Disorder, Treatment-Resistant

United States, France, Poland, United Kingdom, Belgium, Germany, Taiwan, Spain, Argentina, Mexico, Bulgaria, Malaysia, South Africa, Turkey, Canada, Korea, Republic of, Brazil, Estonia, Hungary, Lithuania, Slovakia, Sweden, Czechia, A... and more
Janssen Research & Development, LLC

Completed

A Study to Assess the Effect of Multiple-Dose Administration of JNJ-42847922 on Midazolam and Warfarin in Healthy Participants

Healthy

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacodynamics, Pharmacokinetics, and Safety Study of Hydrochlorothiazide and Canagliflozin in Healthy Volunteers

Healthy
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate Skin Irritation and Photo Irritation of JNJ 10229570-AAA on Intact Skin of Japanese Healthy Male Participants

Healthy Volunteers

Japan
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants

Obesity

United States, Belgium, United Kingdom, Sweden, Poland, Canada
Janssen Pharmaceutica N.V., Belgium

Completed

A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-64041575 in Adult Participants With Various Degrees of Renal Function

Renal Insufficiency

Germany
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Drug Interaction Study of Warfarin and Canagliflozin in Healthy Adult Volunteers

Healthy

Belgium
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

Japan
Janssen Research & Development, LLC

Completed

A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors

Advanced Solid Neoplasms

Spain, Israel
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics and Safety of Digoxin in Healthy Volunteers.

Healthy
Janssen-Cilag International NV

Completed

A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive Disorder

Major Depressive Disorder

Belgium, Germany, Netherlands
Johnson & Johnson Pharmaceutical Research & Development...

Completed

An Efficacy Study of JNJ-39220675 and Pseudoephedrine in Participants With Allergic Rhinitis

Allergic Rhinitis

Canada
Janssen Research & Development, LLC

Recruiting

A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer (PolyDamas)

Carcinoma, Non-Small-Cell Lung

Korea, Republic of, United States, Malaysia, Turkey
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin (JNJ-28431754) in Healthy Indian Volunteers

Healthy

India
Janssen Research & Development, LLC

Completed

A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection

Hepatitis B, Chronic

France, Taiwan, Canada, United States, Germany, Spain, Japan, Russian Federation, Turkey, United Kingdom
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Investigate Whether Pharmacokinetic and Pharmacodynamic Interactions Exist Between Metformin and Canagliflozin (JNJ-28431754) in Healthy Volunteers

Healthy

United States
Janssen Research & Development, LLC

Completed

A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic Function

Hepatic Impairment

United States
Janssen Pharmaceutical K.K.

Completed

A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Lymphocytic Leukemia

Japan
Janssen Research & Development, LLC

Completed

A Study of Seltorexant (JNJ-42847922) After Single-Dose Administration in Healthy Participants

Healthy

United States
Janssen Vaccines & Prevention B.V.

Completed

A Shedding Study of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF) Vaccine in Adults

Healthy

Belgium
National Cancer Institute (NCI)

Recruiting

Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland

Prostate Adenocarcinoma | Localized Prostate Carcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8

United States
Janssen Pharmaceutical K.K.

Completed

Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate Cancer

Prostatic Neoplasms

Japan
Janssen Research & Development, LLC

Completed

A Study of Apalutamide Administered Orally as Whole Tablets and as a Mixture in Applesauce in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis (ICONIC-LEAD)

Plaque Psoriasis

Germany, United States, Hungary, Italy, Turkey, Korea, Republic of, United Kingdom, China, Taiwan, Poland, Canada, France, Australia, Spain, Argentina, Japan
Herbert Meltzer
Janssen Research & Development, LLC

Completed

Testing the Ability of JNJ-18038683 to Improve Cognition and Reduce Depressive Symptoms in Stable Bipolar Patients

Bipolar Disorder

United States
Janssen Research & Development, LLC

Withdrawn

A Study to Assess the Pharmacokinetics and Pharmacodynamics of JNJ-54452840 in Participants With Heart Failure and Anti-beta1-adrenergic Receptor Autoantibodies

Heart Failure
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacokinetic Dose Proportionality Study of Canagliflozin in Healthy Volunteers

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Abiraterone Following Administration of Abiraterone Acetate Tablets in Healthy Adult Men

Healthy Volunteers

Belgium
Janssen Sciences Ireland UC

Completed

A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

Hepatitis B, Chronic

Belgium, United Kingdom, France, Italy, Germany, Spain, Poland
Janssen Research & Development, LLC

Completed

A Study of JNJ-64300535 in Healthy Participants

Healthy

Belgium
King's College London

Recruiting

Imaging 5HT7 Antagonist Effects in Bipolar Disorder

Bipolar Disorder

United Kingdom
Janssen Sciences Ireland UC

Completed

A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989

Hepatic Impairment

Germany
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Patients With Advanced or Refractory Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Advanced or Refractory Leukemia

United States
Janssen Research & Development, LLC

Terminated

A Study to Investigate Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA Gamma 8) Receptor Occupancy of JNJ-64140284 With Newly Developed Transmembrane AMPA Receptor Regulatory Protein (TARP)-Gamma 8 Positron Emission Tomography (PET) [18F]JNJ-64511070 in Healthy Men

Healthy

Belgium
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease (Autonomy)

Cognitive Dysfunction | Dementia | Alzheimer Disease

United States, Belgium, France, Japan, United Kingdom, Spain, Canada, Australia, Sweden, Netherlands
Janssen Research & Development, LLC

Active, not recruiting

A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL

Lymphoma, Non-Hodgkin | Leukemia, Lymphocytic, Chronic, B-Cell

Denmark, France, Poland, Sweden
Janssen Research & Development, LLC

Active, not recruiting

A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (RAGNAR)

Advanced Solid Tumor

France, United States, Japan, Belgium, United Kingdom, Germany, Korea, Republic of, Taiwan, China, Poland, Italy, Spain, Australia, Brazil, Argentina
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19) (HORIZON 1)

COVID-19 Prevention

United States, South Africa, Brazil
Janssen Research & Development, LLC

Completed

A Study to Evaluate Safety and Immunogenicity of the ExPEC4V Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Participants Aged 18 Years and Older

Healthy

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

Multiple Myeloma

Canada, United States, Germany, Netherlands, Spain

3

Subscribe